[go: up one dir, main page]

WO2008053478A3 - Compositions and methods for inhibiting hiv-1 replication and integrase activity - Google Patents

Compositions and methods for inhibiting hiv-1 replication and integrase activity Download PDF

Info

Publication number
WO2008053478A3
WO2008053478A3 PCT/IL2007/001321 IL2007001321W WO2008053478A3 WO 2008053478 A3 WO2008053478 A3 WO 2008053478A3 IL 2007001321 W IL2007001321 W IL 2007001321W WO 2008053478 A3 WO2008053478 A3 WO 2008053478A3
Authority
WO
WIPO (PCT)
Prior art keywords
replication
compositions
methods
inhibiting hiv
integrase activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2007/001321
Other languages
French (fr)
Other versions
WO2008053478A2 (en
Inventor
Assaf Friedler
Abraham Loyter
Moshe Kotler
Amnon Hizi
Zvi Hayouka
Joseph Rosenbluh
Aviad Levin
Shoshana Loya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Ramot at Tel Aviv University Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Ramot at Tel Aviv University Ltd
Publication of WO2008053478A2 publication Critical patent/WO2008053478A2/en
Publication of WO2008053478A3 publication Critical patent/WO2008053478A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides isolated peptides comprising a fragment of a LEDGF/p75 protein and use of same for treating HIV-1 infection, inhibiting HIV-1 replication and inhibiting DNA binding and 3'-end processing activity of HIV-1 integrase protein.
PCT/IL2007/001321 2006-10-30 2007-10-30 Compositions and methods for inhibiting hiv-1 replication and integrase activity Ceased WO2008053478A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85513006P 2006-10-30 2006-10-30
US60/855,130 2006-10-30

Publications (2)

Publication Number Publication Date
WO2008053478A2 WO2008053478A2 (en) 2008-05-08
WO2008053478A3 true WO2008053478A3 (en) 2008-07-03

Family

ID=39137007

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2007/001321 Ceased WO2008053478A2 (en) 2006-10-30 2007-10-30 Compositions and methods for inhibiting hiv-1 replication and integrase activity

Country Status (1)

Country Link
WO (1) WO2008053478A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006229B2 (en) 2011-04-21 2015-04-14 Gilead Sciences, Inc. Benzothiazole compounds and their pharmaceutical use
US9102614B2 (en) 2010-07-02 2015-08-11 Gilead Sciences, Inc. Naphth-2-ylacetic acid derivatives to treat AIDS
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US9296758B2 (en) 2010-07-02 2016-03-29 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0701253D0 (en) 2007-01-23 2007-02-28 Diagnostics For The Real World Nucleic acid amplification and testing
EP2334318B1 (en) 2008-10-06 2016-02-10 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Hiv-1 integrase derived stimulatory peptides interfering with integrase - rev protein binding
TWI480271B (en) 2012-04-20 2015-04-11 Gilead Sciences Inc Medical compound
CA2873771A1 (en) * 2012-05-21 2013-11-28 The Regents Of The University Of Colorado, A Body Corporate Ledgf peptides and formulations thereof for treatment of degenerative disorders

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHEREPANOV PETER ET AL.: "Identification of an evolutionarily conserved domain in human lens epithelium-derived growth factor/transcriptional co-activator p75 (LEDGF/p75) that binds HIV-1 integrase", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 47, 19 November 2004 (2004-11-19), pages 48883 - 48892, XP002478701, ISSN: 0021-9258 *
CHEREPANOV PETER ET AL.: "Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 102, no. 48, November 2005 (2005-11-01), pages 17308 - 17313, XP002478700, ISSN: 0027-8424 *
DATABASE PDB [online] 24 September 2005 (2005-09-24), CHEREPANOV P., AMBROSIO A.L., RAHMAN S., ELLENBERGER T., ENGELMAN A.: "Structural basis for the recognition between HIV-1 integrase and LEDGF/p75", XP002478702, retrieved from EBI accession no. PDB:2B4J Database accession no. 2B4J *
DE RIJCK JAN ET AL.: "Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication", 20 September 2006 (2006-09-20), XP002478856, Retrieved from the Internet <URL:http://jvi.asm.org/cgi/reprint/JVI.00801-06v1> [retrieved on 20080430] *
HAYOUKA ZVI ET AL.: "Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium", PNAS, vol. 104, no. 20, 15 May 2007 (2007-05-15), pages 8316 - 8321, XP002478699 *
LATAILLADE MAX ET AL.: "The hunt for HIV-1 integrase inhibitors.", AIDS PATIENT CARE AND STDS JUL 2006, vol. 20, no. 7, July 2006 (2006-07-01), pages 489 - 501, XP009099694, ISSN: 1087-2914 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9102614B2 (en) 2010-07-02 2015-08-11 Gilead Sciences, Inc. Naphth-2-ylacetic acid derivatives to treat AIDS
US9296758B2 (en) 2010-07-02 2016-03-29 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds
US9006229B2 (en) 2011-04-21 2015-04-14 Gilead Sciences, Inc. Benzothiazole compounds and their pharmaceutical use
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS

Also Published As

Publication number Publication date
WO2008053478A2 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
WO2008053478A3 (en) Compositions and methods for inhibiting hiv-1 replication and integrase activity
EP2537524A3 (en) Treatment of T-cell mediated diseases
WO2004014312A3 (en) Small-mer compositions and methods of use
WO2005115398A3 (en) Hiv integrase inhibitors
WO2007075525A3 (en) Combination of an iap-inhibitor and a taxane7
MX2009000285A (en) Substituted piperidines that increase p53 activity and the uses thereof.
WO2009070294A3 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
WO2007016538A3 (en) Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
WO2005002526A3 (en) Method and compositions for treatment of viral infections
WO2005077050A3 (en) Hiv integrase inhibitors
WO2009020559A3 (en) Agents that inhibit p-tefb interactions and methods of use thereof
WO2008142303A3 (en) Use of an anti-cxcr4 antibody for treating cancer
WO2008088524A3 (en) Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor
ATE319439T1 (en) AGENTS FOR THE TREATMENT OF DISEASES OF THE TRACHEO-BRONCHIAL TRACT, IN PARTICULAR COPD
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2008051448A3 (en) Methods and compositions for efficient removal of protein a from binding molecule preparations
WO2007019098A3 (en) Hiv integrase inhibitors
WO2008068765A3 (en) Compositions and methods for inhibiting hiv-1 replication and integrase activity
WO2006137938A3 (en) Antibody fragments for protection from pathogen infection and methods of use thereof
WO2004037192A3 (en) Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases
WO2007143548A3 (en) Myxoma virus mutants for cancer treatment
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
WO2005070042A8 (en) Novel chemical compounds
ATE540971T1 (en) PROTEIN KINASE C INHIBITORS FOR PREVENTING INSULIN RESISTANCE AND TYPE 2 DIABETES

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07827295

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07827295

Country of ref document: EP

Kind code of ref document: A2